Breast Cancer

Breast Cancer, Nektar Therapeutics said its experimental drug failed to meet the main goal in previously treated patients with advanced breast cancer in a late-stage study. The drug, NKTR-102, provided a 2.1 month improvement in median overall survival over patients on chemotherapy in the trial, but the effect was not statistically significant,.. Continue Reading...